Philadelphia University + Thomas Jefferson University
Sidney Kimmel Medical College
Department of Medicine

Squires, Kathleen

< Back

Profile

key018

Kathleen Squires, MD

Contact Dr. Squires

1015 Chestnut Street
Suite 1020
Philadelphia, PA 19107

(215) 955-7785
(215) 955-9362 fax

Medical School

Medical College of Pennsylvania

Residency

Medical College of Pennsylvania (MCP)

Fellowship

Cornell Medical Center - New York Hospital

Board Certification

Internal Medicine
Infectious Disease

Hospital Appointment

Thomas Jefferson University Hospital

Expertise & Research Interests

Dr. Squires joined the Division as Director in September 2005. Her research interests have been concentrated in the field of HIV infection; specifically antiretroviral drug development and identification of novel treatment strategies as well as the course of HIV infection in women. She supervised a three thousand patient HIV clinic and was the Principal Investigator for the USC Clinical Trials Unit at the Keck College of Medicine of the University of Southern California.

Publications

Most Recent Peer-Reviewed Publications

  1. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
  2. Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks
  3. Influence of sex/gender and race on responses to raltegravir combined with tenofovir-emtricitabine in treatment-naive human immunodeficiency virus-1 infected patients: Pooled analyses of the STARTMRK and QDMRK studies
  4. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study
  5. Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine
  6. HIV infection: Antiretroviral therapy
  7. Immune reconstitution but persistent activation after 48 weeks of antiretroviral therapy in youth with pre-therapy CD4 >350 in ATN 061
  8. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the hiv reverse transcriptase inhibitor tenofovir, in HIV-infected adults
  9. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women
  10. Bone health and human immunodeficiency virus infection
  11. Insights on GRACE (Gender, Race, and Clinical Experience) from the patient's perspective: GRACE participant survey
  12. Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK study
  13. Inflammatory biomarker changes and their correlation with framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES
  14. Cobicistat: A new boost for the treatment of human immunodeficiency virus infection
  15. Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-Week outcomes from GRACE
  16. Risk perceptions after human papillomavirus vaccination in HIV-infected adolescents and young adult women
  17. Gender-sensitive reporting in medical research
  18. Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in HIV-1-infected women
  19. Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.
  20. ARIES 144 week results: Durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine